Derek DiRocco, PhD

Partner

Derek DiRocco is a Partner at RA Capital Management. Derek’s primary responsibilities are to work on both public and private investments and serve as a Board Director for 89Bio, Achilles Therapeutics, iTeos Therapeutics, Connect Bio, CANbridge, and Werewolf Therapeutics. Prior to RA Capital, Derek covered solid tumor oncology landscapes. Derek conducted his postdoctoral research at Brigham and Women’s Hospital/​Harvard Medical School, where he researched the role of the Wnt signaling pathway in mouse models of kidney disease, and was part of a team that discovered a stem cell subtype responsible for solid organ fibrosis. Derek holds a BA in Biology from Holy Cross College and a PhD in Pharmacology from the University of Washington.